Longevity & AgingGene Therapy for Brain-Destroying Lysosomal Diseases Is Finally Working
Hematopoietic stem progenitor cell gene therapy (HSPC-GT) is emerging as a transformative treatment for neurometabolic lysosomal storage diseases (LSDs). By harvesting a patient's own stem cells, inserting a corrective gene via lentiviral vectors, and reinfusing them after conditioning chemotherapy, the approach generates modified cells that engraft, differentiate, and continuously produce therapeutic enzymes at supranormal levels — including inside the brain. Clinical trials across MPS I, II, III, Fabry, Pompe, MLD, and X-ALD show stabilization of neurological function, reduced substrate accumulation in CSF, and meaningful quality-of-life improvements. Two products — Libmeldy (MLD) and Skysona (X-ALD) — have received market authorization in the EU and USA, validating the platform and raising hope for other ultra-rare LSDs with no adequate treatment.
